ArticleLiver cancer2025
Patterns and Prognostic Stratification of Recurrence after Thermal Ablation in Patients with Hepatocellular Carcinoma.
Article in Liver cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Taiwan Academy of Tumor Ablation (TATA) consensus on hepatocellular carcinoma ablation.Hepatology international · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Recurrence rates following thermal ablation for hepatocellular carcinoma (HCC) remain high, but the patterns of recurrence and post-recurrence outcomes are not well characterized. This study aimed to investigate the recurrence patterns and long-term post-recurrence survival (PRS) in patients with HCC after thermal ablation to inform post-recurrence treatment strategy. Methods: A retrospective analysis was conducted on 824 patients who underwent thermal ablation for HCC between 2007 and 2023. Recurrence patterns and factors influencing PRS in patients with recurrence within and beyond the Milan criteria were evaluated. An independent cohort of 198 patients served as an external validation cohort for the prognostic models. Results: During a median follow-up of 54.5 months, 536 patients experienced HCC recurrence, with 83.8% within and 16.2% beyond Milan criteria. For patients with recurrence within Milan criteria, early recurrence, recurrent tumor size, AFP, ALBI grade, and FIB-4 score were independent predictors of PRS. In patients with recurrence beyond Milan criteria, diabetes mellitus, macrovascular invasion, AFP, ALBI grade, and FIB-4 score independently predicted PRS. Based on PRS predictors, a risk model stratified patients with recurrence within Milan criteria into four risk groups, with median PRS of 103.7, 65, 48.7, and 28.6 months, respectively ( Conclusions: PRS in patients with recurrent HCC after thermal ablation is significantly influenced by recurrence patterns, tumor characteristics, and host factors. These findings may guide post-recurrence treatment strategies and optimize the timing of salvage liver transplantation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.